CFR CAR19 iT cell therapy(Fate Therapeutics)

N/A

Report date: 2023/01/03 18:04:17

Base Information

Drug NameCFR CAR19 iT cell therapy(Fate Therapeutics)

Drug Alias NameCFR-CAR-19

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Stem cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocytes stimulantsAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFate Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A